Skip to main content
PLOS Global Public Health logoLink to PLOS Global Public Health
. 2024 Mar 28;4(3):e0003069. doi: 10.1371/journal.pgph.0003069

HIV stigma and other barriers to COVID-19 vaccine uptake among Georgian people living with HIV/AIDS: A mixed-methods study

Tamar Zurashvili 1,2,*,#, Tsira Chakhaia 2,3,#, Elizabeth J King 4,, Jack DeHovitz 5,, Mamuka Djibuti 2,
Editor: Muhammad Sale Musa6
PMCID: PMC10977874  PMID: 38547297

Abstract

We conducted a study in Georgia to examine behavioral insights and barriers to COVID-19 vaccine uptake among people living with HIV (PLWH). Between December 2021-July 2022, we collected quantitative data to evaluate participants’ demographics, COVID-19 knowledge, attitude, perception, and HIV stigma as potential covariates for being vaccinated against COVID-19. We conducted a multivariate analysis to define the factors independently associated with COVID-19 vaccination among PLWH. We collected qualitative data to explore individual experiences of their positive or negative choices, main barriers, HIV stigma, and preferences for receiving vaccination. Of the total 85 participants of the study, 52.9% were vaccinated; 61.2% had concerns with the disclosure of HIV status at the vaccination site. Those who believed they would have a severe form of COVID-19 were more likely to be vaccinated (OR = 23.8; 95% CI: 5.1–111.7). The association stayed significant after adjusting for sex, age, education level, living area, health care providers’ unfriendly attitudes, and their fear of disclosing HIV status at vaccination places. Based on the qualitative study, status disclosure was a significant barrier to receiving care; therefore, PLWH prefer to receive COVID-19 vaccination integrated in HIV services. Conclusions: In this study, around half of the participants were not vaccinated against COVID-19. The main reasons for not being vaccinated included stigma, misleading health beliefs, and low awareness about COVID-19. An integrated service delivery model may improve vaccination uptake among PLWH in Georgia.

Introduction

HIV/AIDS and SARS-CoV-2 (COVID-19) are two major public health problems worldwide. Compared with the HIV-negative persons, people living with HIV(PLWH) have greater risk of contracting, developing complications, and dying from COVID-19 [13]. Therefore, vaccinating PLWH against COVID-19 is a priority public health measure to avoid complications from the disease and stop the spread of the virus. The existing literature suggests that COVID-19 vaccines are effective in PLWH [4, 5], although global uptake among this population has been reported to be 56.6% [6]. Substantial regional variations in COVID-19 vaccine uptake among PLWH are evident, with notably high rates observed in the European Region (90.1%) and the Region of the Americas (71.6%), while lower rates are reported in the Eastern Mediterranean Region (19.3%) and the African Region (35.5%) [6]. Studies also indicate that COVID-19 vaccine hesitancy (defined by the World Health Organization as the delay in acceptance or refusal of vaccination despite the availability of vaccination services [7]) is higher among this population and that factors influencing vaccine hesitancy are different for PLWH compared to HIV-negative individuals. Factors contributing to COVID-19 vaccine hesitancy among PLWH globally include perceived risks [8, 9], safety concerns [1013], distrust in vaccine information sources, doubts about COVID-19 existence and low-risk perception [10, 14]. The study conducted among PLWH in Southwest Ethiopia indicated that the odds of intention to take the COVID-19 vaccine were 4.1 times higher among those participants who had good knowledge of COVID-19 practice compared with those who had poor knowledge [15]. The study conducted among PLWH in France reported association between a general vaccine refusal, fear of developing side effects and perception of already being immune with COVID-19 and COVID-19 vaccination hesitancy [13].

Vaccine acceptance in Eastern Europe faces challenges, with low proportions of vaccinated individuals and hesitancy influenced by factors such as public confidence in vaccine safety, efficacy, literacy, and trust in the government and medical system, underscoring the need for targeted public health initiatives to enhance COVID-19 vaccine uptake in the region [16]. In Eastern Europe and Central Asian (EECA) countries, where the HIV epidemic is escalating, our search revealed a notable gap in studies on COVID-19 vaccine acceptance, uptake and hesitancy among PLWH. This gap is particularly significant given the continued growth of the HIV epidemic in the region [17], making PLWH a crucial focus, especially considering the heightened risks associated with COVID-19. Against a backdrop of historical mistrust among citizens from the former Soviet Union towards healthcare, public institutions, medical personnel, and vaccination, a global survey identified some post-Soviet countries as having the highest hesitancy in Europe [18]. Recent research on the effects of exposure to Soviet communism on vaccine trust highlighted how socio-political regimes can adversely impact trust in vaccines, stemming from a lack of confidence in both government and healthcare providers [19]. The scarcity of data on vaccine uptake among PLWH in EECA, coupled with the unique historical context, underscores the importance of nuanced consideration in approaching vaccination attitudes. Importantly, the observed stance in the general population may not necessarily align with that of PLWH, highlighting the need for targeted research to inform tailored public health strategies for this high-risk population. The issue of COVID-19 vaccination among PLWH is important to explore in Georgia for several reasons. Foremost, overall COVID-19 vaccination rates remain suboptimal in the country. Georgia received the first batch of COVID-19 vaccine in March 2021. As of July 1st, 2022, 48.5% of adult population ages >18 was vaccinated with at least one dose and 44.9% was fully vaccinated in the same age group [20]. There is no data reported on COVID-19 vaccination specifically among PLWH in Georgia; however, we anticipate that this rate is lower compared to the general population given that little attention has been given to PLHW in the COVID-19 response in the country. To date, the country has not developed any specific plan or campaign for the vaccination of PLWH that would consider their health condition, including immune status and potential comorbidities. The other important factors impacting on vaccine uptake could be the lack of safety data on COVID-19 vaccines among PLWH as well as HIV-related stigma. To mitigate the negative effects of COVID-19 in PLWH and support the improvement of COVID-19 vaccination among this group, we explored individual level barriers by assessing the knowledge and attitude towards COVID-19 vaccination of PLWH, COVID-19, and HIV-related dual stigma and discrimination, including stigma in healthcare settings and factors associated with vaccine uptake. To explore behavioral insights and barriers to COVID-19 vaccination among PLWH, we used the Health Belief Model (HBM) [21], which has been widely used to look at COVID19 vaccine acceptance and uptake [22, 23]. The model suggests that an individual’s knowledge and beliefs about health problems, perceived threats, benefits, barriers, including stigma, have a significant influence on whether and why this individual will take action to prevent or control his/her health condition.

Methods

A cross-sectional, mixed-methods research study was conducted among adults living with HIV (>18 years old) in Georgia. The study was conducted throughout Georgia, covering the capital city, Tbilisi, as well as various regions, including Kakheti, Imereti, Guria, Samegrelo, and Ajara. Utilizing different online meeting options (e.g. Zoom, WhatsApp, Viber number, Skype, Cell Phone) during the data collection facilitated interviews with participants from diverse geographical locations.

Quantitative phase

Recruitment

For the quantitative component, PLWH were recruited using a respondent-driven sampling (RDS) from the beneficiaries of a PLWH community-based organization “Real People Real Vision”. Eligibility criteria for PLWH included age 18 or older with self-reported HIV positive status.

Data collection

Two study interviewers conducted data collection for the quantitative part of the study. Participants were offered the opportunity to take part in the interview via the different online meeting options (Zoom, WhatsApp, Viber number, Skype, Cell Phone). Once contacted via the preferred mode of communication, the study interviewer first conducted screening for eligibility using short screener questionnaire for PLWH, and after successful screening performed an interview using a structured questionnaire. To ensure effective recruitment and participation in the study, monetary incentives were provided to all participants.

Measurements

The structured questionnaire was developed for the quantitative data collection considering the constructs of HBM with concrete questions for each component described below.

The outcome measure for this study was self-reported COVID-19 vaccination status, dichotomized with “Yes” and “No” responses.

Sociodemographic characteristics. The sociodemographic characteristics were participants age, sex, area of residence, education level and financial situation.

COVID-19 knowledge, attitude, perception. Information on respondents’ knowledge about COVID-19 was collected by asking whether COVID-19 and influenza were the same disease (respondents could respond, “Yes,” “No,” or “Don’t know.”), about transmission rout (i.e., droplets, sexual intercourse, blood borne) and existence of COVID-19 vaccines and medications (“Yes,” “No,” or “Don’t know.”). These questions had previously been used in a study on COVID-19 knowledge among Georgian population [24]. Attitude and perception questions asked about COVID-19 self-protection and avoidance ability, importance of COVID-19 vaccination, ways of improving the COVID-19 vaccination in general and among PLWH, and about motivations for getting vaccination, self-perceived probability and severity, perceptions related to coping with stress and recovering, trust in and use of information sources. These questions were adapted from WHO guidance for conducting behavioral insights studies related to COVID-19 [25].

HIV stigma. For measuring HIV stigma, we used 12-item HIV Stigma Scale [26]. Subscales included personalized stigma, disclosure concerns, concerns with public attitudes and negative self-image. Personalized stigma was assessed by positive response to the following three statements: “People I care about stopped calling after learning I have HIV”, “I have lost friends by telling them I have HIV” and “Some people avoid touching me once they know I have HIV”. Questions on HIV status discloser asked about keeping HIV status a secret, considering it risky to disclose it and being very careful who to tell their HIV status and positive responses indicating stigmatized attitude. Concerns about public attitudes included the following statements: “most people believe a person who has HIV is dirty; "people with HIV are treated like outcasts” and “most people are uncomfortable around someone with HIV”. Negative self-image due to being infected was assessed by positive response to the following three statements: “I feel guilty because I have HIV”, “people’s attitudes about HIV make me feel worse about myself” and “I feel I’m not as good a person as others because I have HIV”. All questions had “Yes”, “No”, “Don’t know” options for answers.

Statistical analysis

OpenEpi v3.03, an open-source tool, was employed to determine the sample size for this study. With a 5% margin of error and a 95% confidence interval, and considering a population size of 9,400, as estimated by the World Health Organization for people living with HIV in Georgia in 2018, the recommended sample size was determined to be 370. This calculation assumed a 50% response distribution.

The main outcome of this study was binary variable—COVID-19 vaccination status (vaccinated/not vaccinated). First, bivariate analyses were used to compare PLWH’s different characteristics and outcomes. We used Chi-square and Fisher’s exact tests for categorical variables and t-test and Wilcoxon rank sum for continuous variables where appropriate. Second, we used simple logistic regression with a binary variable as the outcome. For multivariable analyses, we used logistic regression to evaluate binary variable—COVID-19 vaccination status among PLWH with different characteristics. To build the model, we used stepwise regression. First, we evaluated all variables for their unique contribution in the model. Second, if one did not contribute, we removed it from the model. However, we reentered it later, if this variable was able to explain a bit more significant variance in the dependent variable than it did when it first came in. Co-variates identified by a directed acyclic graph and/or co-variates with a p-value <0.05 in the bivariate analysis were included in the multivariable analysis. We report unadjusted and adjusted odd ratios (ORs) with 95% Confidence Intervals (CIs). A p-value of <0.05 was considered significant.

Qualitative phase

Recruitment

For the qualitative part we selected respondents from the pool of quantitative participants who expressed interest during the survey to subsequently participate in an in-depth interview (IDI), considering the saturation of the data.

Data collection

Two researchers experienced in qualitative research conducted IDIs among PLWH. A total of 20 individual IDIs were conducted between May-July 2022. PLWH participated in IDIs via different online meeting options (WhatsApp, Viber number, Skype, Cell Phone). The average duration for IDI was 1 hour. The IDIs were audio recorded with participants’ consent. The recordings were then transcribed verbatim and any potential identifying information removed from the transcripts.

Measurements

A semi-structured questionnaire was developed for collecting data for the qualitative phase. The topics covered by the IDI guide included the participants’ individual experiences with vaccination, including probing questions about the factors that led to their positive or negative choices; main barriers, including HIV stigma and facilitators; personal attitudes toward the enhancement of the vaccination process; and preferences for the locations for receiving vaccination.

Statistical analysis

The data was analyzed using an interpretive approach and categorized to identify key themes and patterns according to the HBM. Categories that followed the main topics of the interview guide, included perceived risks, attitudes barriers and facilitators that influence an individuals’ decision about getting COVID-19 vaccines.

Ethics approval

The institutional review board of the Georgian National Centre for Disease Control and Public Health (certificate IRB00002150) approved this study. All respondents were informed that their participation was voluntary and signed the informed consent form before completing the questionnaire or IDI.

Results

Quantitative phase

In Georgia, between December 2021—July 2022, 85 PLWH were screened for study eligibility, and all were enrolled (S1 Data). All of them completed the quantitative questionnaire. We observed a considerably low participation rates (85 enrolled vs 370 planned) in our study. This was one of the first studies among PLWH that used online interviewing, which might result in a low response rate. Another factor contributing to low participation rates could be accounted to widespread and deeply rooted stigma [27] towards HIV in Georgia, which could prevent PLWH’s participation in the study (even though PLWH community-based organization supported the recruitment). Another factor for consideration is the time frame of the study, which did not allow to further continue enrolment of study participants.

The median age of the participants was 43 years (IQR = 38–48). 50.6% (n = 43) of all participants were male, and 3.5% (n = 3) did not identify themselves as a man or woman. Thirty eight percent (n = 32) and 45.9% (n = 39) of all participants had completed general secondary and high education institutions, respectively. More than half of the participants reported living in urban areas, and only a fifth of all participants lived alone. Nearly all (n = 83) claimed that their financial condition worsened or remained the same during the past three months (Table 1).

Table 1. Socio-demographic characteristics of PLWH (n = 85) and COVID-19 experience, Georgia, 2022.

Continuous Characteristics Median (IQR) Average (SD)
Age 43 (38–48) 43(9)
Categorical Characteristics N %
Sex 
 Male 43 50.6%
 Female 39 45.9%
 Other 3 3.5%
Education 
 Incomplete general secondary education 2 2.4%
 complete general secondary education 32 37.6%
 professional education 10 11.8%
 Incomplete high education (undergraduate) 2 2.4%
 Complete high education (undergraduate) 39 45.9%
Living area 
 Urban 53 62.4%
 Reginal Center/town 18 21.2%
 Village 14 16.5%
Lives alone
 Yes 17 20.0%
 No 68 80.0%
Financial situation over the past 3 months 
 Improved 2 2.4%
 Remains the same 28 32.9%
 Worse 55 64.7%
Vaccinated 
 Yes 45 52.9%
 No 40 47.1%
To your knowledge, are you, or have you been, infected with COVID-19? 
 Yes 47 55.3%
 No 38 44.7%
Do you know people in your immediate social environment who are or have been infected with COVID-19
 Yes 81 95.3%
 No 4 4.7%
Do you know people someone who died from COVID-19
 Yes 52 61.2%
 No 33 38.8%

Knowledge

Less than a fifth of the respondents believed that influenza and COVID-19 are the same diseases, and around 15% (n = 12) of the interviewed participants could not answer the question about the transmission route for COVID-19. Moreover, 3.5% (n = 3) of the respondents did not believe in and 14.1% (n = 12) did not know about existence of COVID-19 vaccines. Finally, only a third of all participants believed that there are no antiviral medications against COVID-19; the rest of the respondents either thought anti-COVID-19 drugs exist or were unsure about this. Perceived Risk/Attitude: Half of the respondents did not agree that PLWH have more probability of getting COVID-19 compared to the general public. Moreover, almost half of all respondents perceived that they would not have severe forms of disease if infected with COVID-19. Almost half of the interviewed PLWH reported feeling fear and stress. COVID-19 made 40% (n = 34) of all respondents felt total helplessness; another third of the respondents held the belief that COVID-19 is something they were not confident to combat, as they believed that avoiding COVID-19 infection to be extremely difficult. At the same time, almost half of the respondents perceived that the COVID-19 situation was overhyped in the media. Along these same lines, the most trusted source of information about COVID-19 was reported to be a personal doctor among the PLHW who participated in our study. As for the attitude toward recommendations, most participants (80%, n = 68) considered mask use, hand washing, social distancing, and avoiding gatherings as activities that can help to prevent COVID-19. In contrast, less than half of the participants believed that vaccination is a way to protect oneself from COVID-19. However, almost 65% (n = 55) of participants noted that COVID-vaccination is also essential and safe for both the general public and specifically for PLWH. HIV Stigma: Personalized stigma was expressed by more than a quarter of the participants, with 25.9% (n = 22) stating that their close people stopped calling after learning their status, 27.1% (n = 23) lost friends and people avoid contact with them once they know about their status. Unlike personalized stigma, HIV status disclose concerns were more prevalent in our study participants: 34.1% (n = 29) trying hard to keep their status a secret, 47.1% (n = 40) considering it risky to disclosing their status and more than 70% (n = 62) being very careful who they tell their HIV status. In terms of concerns about public attitudes 44% (n = 37) of our study participants think that most people believe a person who has HIV is dirty; 56.5% (n = 48) stated that people with HIV are treated like outcasts and 74% (n = 63) indicated that most people are uncomfortable around someone with HIV. PLWH’s negative self-image due to being infected ranged from 8% (n = 7) feeling not being a good person because of HIV to 35% (n = 30) feeling worse about themselves due to people’s attitudes about HIV. Benefits and barriers: For most participants (72.9%, n = 62), the main benefit of the COVID-19 vaccination was that after vaccination, they would not have severe forms of COVID-19. As for barriers, 61.2% (n = 52) considered the risk of disclosing their HIV status to vaccine providers as the main barrier. Supposedly due to this barrier, most of the respondents (72.9%, n = 62) thought that having vaccination services at HIV service sites would help to improve the COVID-19 vaccination among PLWHIV. It is worth noting that PLWH did not consider HIV status-related health conditions as a barrier to vaccination (Table 2).

Table 2. Knowledge, attitude and practice, and HIV stigma experience of PLWHs (n = 85), Georgia, 2022.
COVID-19 Knowledge
  n %
Are coronavirus and influenza the same diseases?
 Yes 15 17.6%
 No 52 61.2%
 Do not know 18 21.2%
COVID-19 virus transmission route according to respondents
 Droplets 73 85.9%
 Sexual intercourse 1 1.2%
 Blood Borne 1 1.2%
 Do not know 10 11.8%
Does a vaccine against COVID-19 exist?
 Yes, and it is available in Georgia 67 78.8%
 Yes, and it is not available in Georgia 3 3.5%
 No 3 3.5%
 Do not know 12 14.1%
Do antiviral medications against COVID-19 exist?
 Yes 16 18.8%
 No 28 32.9%
 Do not know 41 48.2%
COVID-19 attitude: how to manage
  n %
How can you avoid COVID-19?
 Vaccination 41 48.2%
 Mask use 64 75.3%
 Social distancing 72 84.7%
 Avoiding gathering 76 89.4%
 Hand washing 75 88.2%
What can help to improve the C19 vaccination among PLWH?
 Make the process simpler 10 11.8%
 Make it mandatory 36 42.4%
 Provide some monetary incentives/lottery 29 34.1%
 Allow only vaccinated people in the public spaces 29 34.1%
 Having the vaccination services at HIV service sites (integrated services 62 72.9%
What do you think helps (helped or would help) you as an individual to get COVID-19 vaccination
 Advice/encouragement from my personal doctor 58 68.2%
 Advice/encouragement from other HCW or social worker 26 30.6%
 Advice/encouragement from peers 26 30.6%
 Messages/information from TV/social media 13 15.3%
How can the COVID-19 situation be handled through government policies?
 By promoting COVID-19 vaccines 49 57.6%
 By promoting COVID-19 test 34 40.0%
 By exaggeration in restrictions 35 41.2%
Benefits and Barriers
n %
What do you think are the benefits of getting vaccinated against COVID-19
 I will not get infected 6 7.1%
 I will not spread the infection 17 20.0%
 I will not have a severe form 62 72.9%
 It will help to avoid restrictions 49 57.6%
What do you think are the barriers to getting vaccinated against COVID-19
 Registration is difficult 4 4.7%
 Vaccination place is far 13 15.3%
 Health care providers are not friendly at vaccination place 38 44.7%
 He/she may need disclose my HIV status and he/she may not want it 52 61.2%
 Vaccines are not available 2 2.4%
HIV Stigma
n %
Personalized stigma
People I care about stopped calling after learning I have HIV
 Yes 22 25.9%
 No 51 60.0%
 Do not know 12 14.1%
I have lost friends by telling them I have HIV
 Yes 23 27.1%
 No 53 62.4%
 Do not know 9 10.5%
Some people avoid touching me once they know I have HIV
 Yes 23 27.1%
 No 48 56.5%
 Do not know 14 16.4%
Disclosure concerns
I work hard to keep my HIV a secret
 Yes 29 34.1%
 No 50 58.8%
 Do not know 6 7.1%
Telling someone I have HIV is risky
 Yes 40 47.1%
 No 32 37.6%
 Do not know 13 15.3%
I am very careful who I tell that I have HIV
 Yes 62 73.8%
 No 19 22.6%
 Do not know 3 3.6%
Concerns about public attitudes
Most people believe a person who has HIV is dirty
 Yes 37 43.5%
 No 28 33.0%
 Do not know 20 23.5%
People with HIV are treated like outcasts
 Yes 48 56.5%
 No 24 28.2%
 Do not know 13 15.3%
Most people are uncomfortable around someone with HIV
 Yes 63 74.1%
 No 13 15.3%
 Do not know 9 10.6%
Negative self-image
I feel guilty because I have HIV
 Yes 13 15.3%
 No 71 83.5%
 Do not know 1 1.2%
People’s attitudes about HIV make me feel worse about myself
 Yes 30 35.3%
 No 43 50.6%
 Do not know 12 14.1%
I feel I’m not as good a person as others because I have HIV
 Yes 7 8.2%
 No 76 89.4%
 Do not know 2 2.4%

Slightly more than half (52.9%; n = 45) of all respondents were vaccinated. In the univariate analyses, being vaccinated was significantly associated with participants’ belief of the probability of developing the severe form of COVID-19 in case of getting infected and living in urban area (Table 3).

Table 3. Different characteristics among vaccinated and not vaccinated PLWH (n = 85), Georgia, 2022.
  PLWH Vaccinated PLWH Not Vaccinated P-value
N (%) N (%)
Sex     0.171
 Male 24 (53.3) 19 (47.5)  
 Female 18 (40.0) 21 (52.5)  
 Other 3 (6.7) 0 (0.0)  
Education     0.152
 Incomplete general secondary education 1 (2.2) 1 (2.5)  
 complete general secondary education 17 (37.8) 15 (37.5)  
 professional education 2 (4.4) 8 (20.0)  
 Incomplete High education  2 (4.4) 0 (0.0)  
 Complete high education  23 (51.1) 16 (40.0)  
Living area     0.0348
 Urban 31 (68.9) 22 (55.0)  
 Regional Center/town 11 (24.4) 7 (17.5)  
 Village 3 (6.7) 11 (27.5)  
Lives alone     0.2772
 Yes 11 (24.4) 6 (15.0)  
 No 34 (75.6) 34 (85.0)  
Financial situation over the past 3 months     0.0561
 Improved 1 (2.2) 1 (2.5)  
 Remains the same 20 (44.4) 8 (20.0)  
 Worse 24 (53.3) 31 (77.5)  
I will not have a severe form     < .0001
 Yes 43 (95.6) 19 (47.5)  
 No 2 (4.4) 21 (52.5)  
Health care providers are not friendly at vaccination place  0.8486
 Yes 19 (42.2) 19 (47.5)  
 No 26 (57.8) 21 (52.5)  
He/she may need disclose my HIV status and he/she may not want it 0.2594
 Yes 13 (32.5) 27 (67.5)  
 No 20 (44.4) 13 (32.5)  
Personalized stigma— I have lost friends by telling them I have HIV 0.5172
 Yes 10 (22.2%) 13 (32.5%)
 No 29 (64.4%) 24 (60.0%)
 Do not know 6 (13.3%) 3 (7.5%)
Disclosure concerns— I am very careful who I tell that I have HIV 0.1356
 Yes 32 (72.7%) 30 (75.0%)
 No 12 (27.3%) 7 (17.5%)
 Do not know 0 (0.0%) 3 (7.5%)
Concerns about public attitudes— Most people are uncomfortable around someone with HIV 0.1744
 Yes 31 (68.9%) 32 (80.0%)
 No 10 (22.2%) 3 (7.5%)
 Do not know 4 (8.9%) 5 (12.5%)
Negative self-image— People’s attitudes about HIV make me feel worse about myself 0.6755
 Yes 17 (37.8%) 13 (32.5%)
 No 23 (51.1%) 20 (50.0%)
 Do not know 5 (11.1%) 7 (17.5%)

The results of the multivariate logistic regression analyses showed that, those who believed they would have a severe form of COVID-19 were more likely to be vaccinated (OR = 23.8; 95% CI: 5.1–111.7). The association stays significant and even increases after adjusting for sex, age, education level, and living area (aOR = 25.0; 95% CI: 5.0–125.0). In the third model, we included the variables about the participants’ opinions on health care providers’ friendly/non-friendly attitudes at vaccination places and fairness in disclosing HIV status during the vaccination. The statistically significant association between vaccination status and belief whether they develop severe form becomes more robust than in the unadjusted model (aOR = 25.7; 95% CI: 5.2–127.0) (Table 4).

Table 4. Unadjusted and adjusted associations between having vaccination and health belief of not having COVID-19 severe form among PLWH (n = 85), Georgia, 2022.
  PLWH Vaccinated N (%) PLWH Not Vaccinated N (%) ORa (95% CI) aORb (95% CI) aORc (95% CI)
I will not have a severe form          
 Yes 43 (95.6) 19 (47.5) 23.8 (5.1–111.7) 25.0 (5.0–125.0) 25.7 (5.2–127.0)
 No 2 (4.4) 21 (52.5) Ref Ref Ref

aOR—unadjusted Odds Ratio

baOR—adjusted Odds Ratio controlled for sex, age, education level, living area

caOR—adjusted Odds Ratio controlled for the variables about the participants’ opinion on Health care providers’ friendly/non friendly attitude at vaccination place and their fair to disclose the HIV status during vaccination process.

Qualitative phase

A subsample of 20 participants completed an IDI in our study between June-July 2022. Among this sample, 12 reported having been vaccinated against COVID-19. Eleven participants were male. The age range was 32–68. The descriptive results below are presented according to the main topics of the IDI guide.

Perceived risks, beliefs and attitudes

During the in-depth interviews, all vaccinated participants recalled the process as a positive experience with medical personnel expressing positive attitude towards them. In the majority of cases, it was their personal decision to get vaccinated. Voluntary vaccination was based on the knowledge of its benefits: “Vaccination was my personal decision. We had a vaccination training at my office, and after that I decided to definitely get vaccinated…”. Personal doctor’s advice or celebrity’s behavior was a trigger for some participants to get vaccination: “I saw some very famous people who got their shots, and I knew that everyone felt good, and I considered it necessary to get the one as well, because it would be good for my health. This helped me to make a decision about vaccination…”.

As for unvaccinated participants, similar to the results of the quantitative component of the study, they mostly talked about the uselessness of vaccine, since they could easily recover from the disease by themselves: “I have a strong immune system… I won’t get a severe form of COVID, so I can handle by myself… I don’t need vaccination…”, or already had contracted COVID-19 and considered it a mild disease with no complications: “I am not vaccinated. I had COVID, it was mild, and I recovered very easily…”. In the majority of cases, unvaccinated participants stated that nothing would change their decision regarding COVID-19 vaccination.

Barriers to COVID-19 vaccination for PLWH

Vaccinated PLWH mostly stated that there are no barriers to COVID-19 vaccination based on their personal experience: “The process of vaccination was really good, I would improve just nothing…”. Both vaccinated and those who were not vaccinated respondents considered lack of information and awareness about COVID-19 vaccines as a significant barrier to COVID-19 vaccination: “The biggest barrier was probably lack of awareness, everyone was talking different things: the church, doctors, media, some of them recommended vaccination and some did no, it was really confusing…”. Another barrier stated by the respondents from both groups was HIV stigma: “Disclosing HIV status is also a problem of our society, as a rule PLWH hide information about it, and they should not, no one hides information about their diabetes, and this should be the case for HIV as well. But nobody is working on this issue, neither doctors, nor the media and it’s very bad…”, however those who were vaccinated either did not have problem with disclosure or just simply did not talk about their status to the medical personnel at the vaccination site. Majority of unvaccinated respondents stated that they simply did not want to be vaccinated, although in case they would decide to get a shot, status disclose would be a challenge for them: “I didn’t even think for a second that I should get vaccinated and if I would want, that factor [status disclosure] would be a barrier for me, I live in a village, and everyone knows me here. Stigma still exists here…”

Integration of services and a trustworthy person

The majority of respondents, both vaccinated and unvaccinated, noted that integrating vaccination services in HIV treatment and care services would be convenient for PLWH: “Yes, it [integration] would be very convenient, I would feel more comfortable with my personal doctor, because I trust her…”. However, those who already got vaccination, do not consider vaccination sites outside HIV services being an issue: “I got vaccination outside HIV care and didn’t have any problem either, but I think it [integration] would be better, my doctor knows my status and I would be more confident…” While talking about most trustworthy person on getting general medical or COVID-19 and vaccination information/advice, the vast majority of participants talked only about their personal doctors/infectious disease specialist.

Discussion

The main finding of our study was the low coverage of vaccination (only slightly more than half) among PLWH. Our finding is slightly lower than a global COVID-19 vaccine uptake among PLWH of 56.6%, but at the same time notably lower than the rate of 90.1% for the European Region as reported by Sulaiman et al. [6]. When considering the broader context, our findings also underscore a significant gap compared to the global vaccine uptake among the general population, which stands at a higher rate of 70.6% [28]. Results from our research highlight three main reasons for PLWH not being vaccinated: misleading health beliefs, low awareness about COVID-19, and stigma.

Most participants believed they have a low probability of developing severe disease after being infected with COVID-19. At the same time, for these respondents, the main benefit of the COVID-19 vaccination was that after vaccination, they would not have severe forms of COVID-19. These contradictory beliefs might cause reluctance regarding the necessity of getting COVID-19 vaccination. Unadjusted and adjusted statistically significant associations between being vaccinated and participants’ opinion of the probability of developing severe COVID-19 in case of getting infected proved the above statement. In-depth interviews, during which unvaccinated respondents mostly talked about the uselessness of COVID-19 vaccines since they could quickly recover from the mild disease with no complications, also confirmed these findings. A systematic review and meta-analysis conducted by Sulaiman et al. reported association of perceived high susceptibility to SARS-CoV-2 infection and a strong belief in the vaccine’s effectiveness and utility with higher COVID-19 vaccine acceptance and uptake among PLWH [6]. HBM constructs, such as perceived severity of COVID-19 infection and perceived benefits of a COVID-19 vaccine have also been linked to vaccination acceptability among general population [29, 30]. The results highlight the interconnected role of risk perception and perceived vaccine benefits in influencing vaccination behavior.

Stigma was another main reason for vaccine non-uptake among PLWH. According to our quantitative analyses, the risk of disclosing their HIV status to vaccine providers is the main barrier for HIV-positive respondents. This finding is in line with our qualitative findings. During the IDIs, respondents noted that PLWH prefer not to disclose information about their HIV status. Supposedly due to this barrier, most PLWH expressed that having vaccination services at HIV service sites would be convenient for getting a vaccination. The study conducted among Chinese PLWH also revealed apprehensions regarding the disclosure of HIV status in the context of COVID-19 vaccination [8]. The low vaccine uptake among marginalized populations, including PLWH in India, has been attributed to factors such as HIV-related stigma, fear of disclosing HIV status, and a scarcity of communication materials tailored for these groups, exacerbating the challenge of combating COVID-19 in these vulnerable communities [31].

Finally, our study’s quantitative and qualitative data showed that PLWH lack knowledge regarding COVID-19. These findings are in line with the study conducted among PLWH in Southwest Ethiopia, which revealed the importance of knowledge in acceptance of COVID-19 vaccination [15]. During the in-depth interviews, unvaccinated respondents named misinformation and lack of trusted sources as significant barriers. Their main concern was that various sources, such as media, health institutions, churches, etc., spread different recommendations regarding the COVID-19 vaccination. The findings from a study conducted in in British Columbia, Canada is also illustrative of inconsistency between the strong recommendations for COVID-19 vaccination for PLWH and existing intentions [32]. Qualitative and quantitative analyses showed that personal doctors are the most trusted source of information for PLWH. Therefore, medical doctors working with HIV-positive people should conduct more COVID-19-related education activities among their patients. The findings from a study among PLWH at a primary care clinic in an urban area of New York City highlight the significance of physicians’ active engagement in individualized education with PLWH leading to an increased vaccine acceptance [33]. HCWs should mainly focus on COVID-19 and HIV dual stigma-related issues and misleading beliefs about developing severe disease among PLWH. A systematic approach to the education sessions would help to increase knowledge and raise awareness about COVID-19 among PLWH.

This study had several limitations. First, the quantitative part was a cross-sectional study, so no causality could be established. The sampling method used (non-probability) for this study makes it difficult to infer the results to the entire PLWH population in Georgia. In our study, the vaccination status was self-reported, however it has been shown that in large observational studies where medical records are not available, self-reported dates and product details for COVID-19 vaccination can be a good substitute [34].

Conclusion

This study was the first in the ECCA region to explore the factors associated with COVID-19 vaccine uptake specifically among PLWH. According to our findings, around half of the PLWH were not vaccinated against COVID-19. We identified that the main reasons for not being vaccinated among PLWH were (1) stigma, (2) misleading health beliefs and (3) low awareness about COVID-19.

COVID-19 awareness raising campaigns and educational sessions should be continually conducted among PLWH. Medical doctors and mainly, HIV service providers as the most trusted source of information for PLWH, should work closely with their patients to support the improvement of COVID-19 vaccination among PLWH in Georgia.

Supporting information

S1 Data. Study dataset.

This dataset comprises anonymized records of participants involved in the study in the format of Excel spreadsheet. It includes information on demographics, COVID-19 vaccination status, knowledge, attitudes, and perceptions related to COVID-19, as well as barriers and facilitators to COVID-19 vaccination. The dataset encompasses data on HIV and HIV and COVID dual stigma among participants.

(XLSX)

pgph.0003069.s001.xlsx (50.5KB, xlsx)

Acknowledgments

The authors thank local PLWH community-based organization “Real People Real Vision” for assistance in the field work and recruitment of participants for this study.

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

The research reported in this publication was supported by the Fogarty International Center, of National Institute of Alcohol Abuse and Alcoholism of the National Institutes of Health under Award Number D43 TW011532 to MD. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Bertagnolio S, Thwin SS, Silva R, Nagarajan S, Jassat W, Fowler R, et al. Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19. Lancet HIV. 2022;9(7):e486–e95. doi: 10.1016/S2352-3018(22)00097-2 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Mellor MM, Bast AC, Jones NR, Roberts NW, Ordonez-Mena JM, Reith AJM, et al. Risk of adverse coronavirus disease 2019 outcomes for people living with HIV. AIDS. 2021;35(4):F1–F10. doi: 10.1097/QAD.0000000000002836 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Ssentongo P, Heilbrunn ES, Ssentongo AE, Advani S, Chinchilli VM, Nunez JJ, et al. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. Sci Rep. 2021;11(1):6283. doi: 10.1038/s41598-021-85359-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Bekker LG, Garrett N, Goga A, Fairall L, Reddy T, Yende-Zuma N, et al. Effectiveness of the Ad26.COV2.S vaccine in health-care workers in South Africa (the Sisonke study): results from a single-arm, open-label, phase 3B, implementation study. Lancet. 2022;399(10330):1141–53. doi: 10.1016/S0140-6736(22)00007-1 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Levy I, Wieder-Finesod A, Litchevsky V, Biber A, Indenbaum V, Olmer L, et al. Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in people living with HIV-1. Clin Microbiol Infect. 2021;27(12):1851–5. doi: 10.1016/j.cmi.2021.07.031 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Sulaiman SK, Musa MS, Tsiga-Ahmed FI, Sulaiman AK, Bako AT. A systematic review and meta-analysis of the global prevalence and determinants of COVID-19 vaccine acceptance and uptake in people living with HIV. Nature Human Behaviour [Internet]. 2024. Jan 1 [cited 2024 Feb 2];8(1):100–14. Available from: https://www.nature.com/articles/s41562-023-01733-3 doi: 10.1038/s41562-023-01733-3 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.WHO. Report of the SAGE Working Group on vaccine hesitancy. 2014. [Google Scholar]
  • 8.Yao Y, Chai R, Yang J, Zhang X, Huang X, Yu M, et al. Reasons for COVID-19 Vaccine Hesitancy Among Chinese People Living With HIV/AIDS: Structural Equation Modeling Analysis. JMIR Public Health Surveill. 2022;8(6):e33995. doi: 10.2196/33995 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Kabir Sulaiman S, Sale Musa M, Isma’il Tsiga-Ahmed F, Muhammad Dayyab F, Kabir Sulaiman A, Dabo B, et al. COVID-19 vaccine hesitancy among people living with HIV (PLHIV) in a low-resource setting: a multi-center study of prevalence, correlates and reasons. Vaccine. 2023. Feb; [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Ekstrand ML, Heylen E, Gandhi M, Steward WT, Pereira M, Srinivasan K. COVID-19 Vaccine Hesitancy Among PLWH in South India: Implications for Vaccination Campaigns. J Acquir Immune Defic Syndr. 2021;88(5):421–5. doi: 10.1097/QAI.0000000000002803 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Shrestha R, Meyer JP, Shenoi S, Khati A, Altice FL, Mistler C, et al. COVID-19 Vaccine Hesitancy and Associated Factors among People with HIV in the United States: Findings from a National Survey. Vaccines. 2022. Mar 10;10(3):424. doi: 10.3390/vaccines10030424 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Liu Y, Han J, Li X, Chen D, Zhao X, Qiu Y, et al. COVID-19 Vaccination in People Living with HIV (PLWH) in China: A Cross Sectional Study of Vaccine Hesitancy, Safety, and Immunogenicity. Vaccines. 2021. Dec 9;9(12):1458. doi: 10.3390/vaccines9121458 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Vallée A, Fourn E, Majerholc C, Touche P, Zucman D. COVID-19 Vaccine Hesitancy among French People Living with HIV. Vaccines. 2021. Mar 24;9(4):302. doi: 10.3390/vaccines9040302 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Bogart LM, Ojikutu BO, Tyagi K, Klein DJ, 1Mutchler MG, Dong L, et al. COVID-19 related medical mistrust, health impacts, and potential vaccine hesitancy among black Americans living with HIV. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2020. Nov 9;86(2). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Mesfin Y, Argaw M, Geze S, Zewdu BT. Factors Associated with Intention to Receive COVID-19 Vaccine Among HIV Positive Patients Attending ART Clinic in Southwest Ethiopia. Patient Prefer Adherence. 2021;15:2731–8. doi: 10.2147/PPA.S342801 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Popa AD, Enache AI, Popa IV, Antoniu SA, Dragomir RA, Burlacu A. Determinants of the Hesitancy toward COVID-19 Vaccination in Eastern European Countries and the Relationship with Health and Vaccine Literacy: A Literature Review. Vaccines. 2022. Apr 23;10(5):672. doi: 10.3390/vaccines10050672 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.The path that ends AIDS: UNAIDS Global AIDS Update 2023. 2023. [Google Scholar]
  • 18.Lazarus JV, Ratzan SC, Palayew A, Gostin LO, Larson HJ, Rabin K, et al. A global survey of potential acceptance of a COVID-19 vaccine. Nat Med. 2021;27(2):225–8. doi: 10.1038/s41591-020-1124-9 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Costa-Font J, Garcia-Hombrados J, Nicinska A. The institutional origins of vaccines distrust: Evidence from former-Soviet countries. PLoS One. 2023;18(3):e0282420. doi: 10.1371/journal.pone.0282420 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.NCDC. National Center for Disease Control and Public Health report on COVID-19 in Georgia. 2020–2022. [Google Scholar]
  • 21.Karen Glanz BV K. Health behavior: theory, research, and practice. Fifth edition 2015. [Google Scholar]
  • 22.Limbu YB, Gautam RK, Pham L. The Health Belief Model Applied to COVID-19 Vaccine Hesitancy: A Systematic Review. Vaccines (Basel). 2022;10(6). doi: 10.3390/vaccines10060973 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Zampetakis LA, Melas C. The health belief model predicts vaccination intentions against COVID-19: A survey experiment approach. Appl Psychol Health Well Being. 2021;13(2):469–84. doi: 10.1111/aphw.12262 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Butsashvili M, Gulbiani L, Kanchelashvili G, Kochlamazashvili M, Nioradze G, Kamkamidze T, et al. Knowledge Related to the Novel Coronavirus (Sars-Cov-2) among Georgian Population. Georgian Med News. 2022(322):66–75. [PubMed] [Google Scholar]
  • 25.SURVEY TOOL AND GUIDANCE Rapid, simple, flexible behavioural insights on COVID-19 [Internet]. 2020. [cited 2023 Oct 1]. Available from: https://studiocovidoms.it/wp-content/uploads/2020/12/Protocollo-studio-Europeo.pdf [Google Scholar]
  • 26.Reinius M, Wettergren L, Wiklander M, Svedhem V, Ekstrom AM, Eriksson LE. Development of a 12-item short version of the HIV stigma scale. Health Qual Life Outcomes. 2017;15(1):115. doi: 10.1186/s12955-017-0691-z [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Magnani R, Sabin K, Saidel T, Heckathorn D. Review of sampling hard-to-reach and hidden populations for HIV surveillance. AIDS. 2005. May;19(Supplement 2):S67–72. doi: 10.1097/01.aids.0000172879.20628.e1 [DOI] [PubMed] [Google Scholar]
  • 28.Our World in Data. Coronavirus (COVID-19) Vaccinations—Statistics and Research [Internet]. Our World in Data. 2023. Available from: https://ourworldindata.org/covid-vaccinations [Google Scholar]
  • 29.Reiter PL, Pennell ML, Katz ML. Acceptability of a COVID-19 vaccine among adults in the United States: How many people would get vaccinated? Vaccine. 2020;38(42):6500–7. doi: 10.1016/j.vaccine.2020.08.043 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Shmueli L. Predicting intention to receive COVID-19 vaccine among the general population using the health belief model and the theory of planned behavior model. BMC Public Health. 2021;21(1):804. doi: 10.1186/s12889-021-10816-7 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.COVID-19 vaccination among key populations and people living with HIV [Internet]. Available from: https://www.fhi360.org/sites/default/files/media/documents/resource-epic-increasing-vaccination-india-success-story.pdf
  • 32.Kaida A, Brotto LA, Murray MCM, Cote HCF, Albert AY, Nicholson V, et al. Intention to Receive a COVID-19 Vaccine by HIV Status Among a Population-Based Sample of Women and Gender Diverse Individuals in British Columbia, Canada. AIDS Behav. 2022;26(7):2242–55. doi: 10.1007/s10461-022-03577-w [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Buckley MaS, Kevinand Spier, Daniel and Stefanov, Dimitre and Ahmadi, Ladan. Attitudes Towards COVID-19 Vaccination in People Living with HIV (PLWHIV) at an Urban Primary Care Clinic.
  • 34.Tjaden AH, Fette LM, Edelstein SL, Gibbs M, Hinkelman AN, Runyon M, et al. Self-Reported SARS-CoV-2 Vaccination Is Consistent with Electronic Health Record Data among the COVID-19 Community Research Partnership. Vaccines (Basel). 2022;10(7). doi: 10.3390/vaccines10071016 [DOI] [PMC free article] [PubMed] [Google Scholar]
PLOS Glob Public Health. doi: 10.1371/journal.pgph.0003069.r001

Decision Letter 0

Steve Zimmerman

22 Dec 2023

PGPH-D-23-01963

HIV stigma and other factors contributing to COVID-19 vaccine hesitancy among Georgian people living with HIV/AIDS: a mixed-methods study

PLOS Global Public Health

Dear Dr. Zurashvili,

Thank you for submitting your manuscript to PLOS Global Public Health. After careful consideration, we feel that it has merit but does not fully meet PLOS Global Public Health’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

The manuscript has been evaluated by three reviewers, and their comments are available below.

The reviewers have raised a number of concerns that need attention, including requests for clarification and additional detail.

Could you please revise the manuscript to carefully address the concerns raised?

One or more reviewers has recommended that you cite specific previously published works. As always, we recommend that you please review and evaluate the requested works to determine whether they are relevant and should be cited. It is not a requirement to cite these works. 

Please submit your revised manuscript by Feb 04 2024 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at globalpubhealth@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pgph/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

We look forward to receiving your revised manuscript.

Kind regards,

Steve Zimmerman, PhD

PLOS Staff Editor

Journal Requirements:

Additional Editor Comments (if provided):

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

**********

3. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: No

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: Dear authors,

You have put tremendous work into preparing this manuscript on a topical issue. I have highlighted some issues that will improve the manuscript's acceptability in the scientific community.

1. Line 26: “Between December-July 2022” State the year of commencement i.e December 2020, December 2021 e.t.c

2. Line 46: Remove “and death”

3. Line 77: Change “not” to “no”

4. Line 143: Please, mention the specific type of regression used i.e binary, multinomial e.t.c

5. A brief description of the study area should also be made.

6. Sample size estimations should be presented. Considering inferential statistics were conducted this is mandatory

Reviewer #2: I appreciate the efforts of the authors in carrying out such a study that explores a critical area of public health and seeks to address the gap in the literature in Geargia. The mixed method approach has provided more insights into the concept and the use of Health Belief Model is appropriate. However, I have some comments that I would like the authors to address:

1. Line 68, are the authors referring to “being immune to COVID-19” OR “…being immune with COVID-19 vaccine hesitancy”

2. It is good that the authors have provided information on the lack of data on vaccine hesitancy among PLHIV in EECA region. However, the flow of the text on P3-4, L64-73 seems to be disjointed. It could be improved by rephrasing and restructuring the sentences. The authors may consider integrating those sentences into one paragraph. Also, it is worthy to note that the attitude observed in the general population may not be reflected among PLHIV.

3. P4, L74 consider changing “There are not data” to “there is no data”

4. The authors highlighted that the COVID-19 vaccine uptake rates in Georgia was suboptimal. One will wonder whether this is associated with availability and accessibility of the vaccine in the country. And to make a fairer comparison with other nations one would like to know when the rollout was commenced in the country. The authors should also consider obtaining an updated vaccination uptake rates in the country, as the data might have changed between July 2022 to date.

5. The sentence that started with “The other important factors….” in L81-83 is not well fitted in that position. According to my understanding, the paragraph was intended to provide justification for conducting the study. Can this sentence be moved to where they discussed the factors associated with vaccine acceptance/hesitancy in other parts of the introduction? This will improve the flow and coherence of the text.

6. Considering the study design, it will be more transparent and appropriate if the authors can provide justification for their sample size.

7. The number of participants given in the caption of table 1 (L184) does not correspond to the total number presented on the table. Similarly, it seems the percentage mentioned in L188 in not correct. Additionally, the authors may consider introducing subheadings in the results section to improve the readability.

8. One will wonder why the authors omitted many important sociodemographic characteristics (such as ethnicity/race, employment status, income etc.) and factors related to the HIV itself (utilization of ART, virologic suppression, etc.) and the COVID-19 vaccine (in the questionnaire), which have been proven to be essential in influencing vaccine acceptance and hesitancy. These would have provided more detailed information about the study population. In addition, have the authors attempted to verify the information provided by the participants with their medical record, especially those related to the vaccination? It is also relevant to include the number doses received by the vaccinated group.

9. The discussion section of the manuscript needs to be improved. I suggest comparing the vaccination rate obtained in this study with what was reported in other parts of the globe among the same population. Also, comparison should be made with the latest data among the general population in the same country. Moreover, since stigma is key aspect of the study, it is important to further support this finding with the available evidence (if any) on the role of stigma on vaccine acceptance/hesitancy.

Reviewer #3: I thank the Editor for giving the opportunity to review this important manuscript. The authors have made a commendable effort to fill in an important gap by reporting COVID-19 vaccination (not hesitancy0 determinants in Georgia. The findings in the study are needed to inform public health in the country. Despite making a lot of effort, I still believe the work needs a significant improvement. My comments to the authors are:

1. Lines 65-66 the authors, without supporting with a reference wrote: “Data for EECA indicates that HIV epidemic continues 66 to grow in the region”

2. In Table 1 title, the authors wrote “…..characteristics of PLWH (n=84) and COVID-19 experience”. Is the n = 84 or 85

3. In Table 2, the authors wrote “What do you think how can be handled the COVID-19 situation”. Please rephrase for clarity.

4. What approach to logistic regression modeling have the authors used? Forward, backward, or stepwise?.

5. Why have the authors not provided the full results of the bivariate and multivariate regression analysis. Please provide this for transparency even if no significant association is found it is still important.

6. The authors have provided data on important behavioural determinants of vaccination in PLHIV but have not included most of these in their regression analysis. Examples include: I will not have a severe form; Health care providers are not friendly at vaccination place; He/she may need disclose my HIV status and he/she may not want it; I have lost friends by telling them I have HIV; I am very careful who I tell that I have HIV; and overall COVID-19 knowledge and attitude. Please report the results of all analysis in full even as a supplementary information.

7. Also 45 out of the 85 participants have been vaccinated according to the authors, while 40 were unvaccinated. It should be noted that these 40 unvaccinated participants can not be said to be hesitant (unless you’ve asked them and they all said they didn’t intend to vaccinate, which you’ve not stated anywhere in your manuscript) according to the WHO SAGE Working group of experts on vaccine hesitancy (delay in acceptance or 51 refusal of vaccination despite the availability of vaccination services) stated and cited by the authors in the introduction. I am saying this because the word hesitancy is included in your manuscript title although not anywhere in the results section. Therefore, the authors need to rephrase the article title and remove the word “hesitancy” from it because its not what they evaluated. Similarly, they should apply this same change to all relevant sections of the manuscript especially the discussion section.

8. Despite only evaluating the determinants of COVID-19 vaccine uptake, the authors kept citing studies on determinants of hesitancy and acceptance in their study. The authors may wish to consider this important manuscript for guide: Sulaiman, S. K., Musa, M. S., Tsiga-Ahmed, F. I. I., Sulaiman, A. K., & Bako, A. T. (2023). A systematic review and meta-analysis of the global prevalence and determinants of COVID-19 vaccine acceptance and uptake in people living with HIV. Nature Human Behaviour, 1-15. https://doi.org/10.1038/s41562-023-01733-3.

I look forward to reading the revised version of this manuscript.

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: Yes: Muhmmad Sale Musa

Reviewer #3: Yes: Sahabi Kabir Sulaiman

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLOS Glob Public Health. doi: 10.1371/journal.pgph.0003069.r003

Decision Letter 1

Muhammad Sale Musa

11 Mar 2024

HIV stigma and other barriers to COVID-19 vaccine uptake among Georgian people living with HIV/AIDS: a mixed-methods study

PGPH-D-23-01963R1

Dear Dr. Zurashvili,

We are pleased to inform you that your manuscript 'HIV stigma and other barriers to COVID-19 vaccine uptake among Georgian people living with HIV/AIDS: a mixed-methods study' has been provisionally accepted for publication in PLOS Global Public Health.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they'll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact globalpubhealth@plos.org.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Global Public Health.

Best regards,

Muhammad Sale Musa, MBBS

Guest Editor

PLOS Global Public Health

***********************************************************

Dear Dr. Zurashvili,

I appreciate your patience during the review process. I also thank you for taking the time to respond to all concerns raised by the reviewers.

While your article has been considered fit for publication, I would like you to address some few issues that will potentially improve the the manuscript. These include:

1. In the introduction section, it will more appropriate to use indefinite articles to introduce some of the sentences. For example, "A study conducted among PLWH in...." sound less definitive and more appropriate in this context than "the study...."

2. From L72-87: Kindly consider replacing "underscoring" or "underscores" in some of the places with another word (synonym) to improve the readability and make the text more engaging

3. Consider correcting L175: "..with a binary variable as the outcome" instead of "with binary variable an outcome".

4. L266: Unvaccinated respondents OR "those who were not vaccinated" sound more appropriate than "Not vaccinated respondents"

5. L392 could be improved by rephrasing it to something like "This study was the first in the ECCA region to explore factors...."

Congratulations to all the authors.

Kindest regards,

Dr. Musa, Guest Editor

Reviewer Comments (if any, and for reference):

The authors have adequately addressed the previous comments.

Reviewer's Responses to Questions

Comments to the Author

Reviewer #3: All comments have been addressed

**********

2. Does this manuscript meet PLOS Global Public Health’s publication criteria? Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe methodologically and ethically rigorous research with conclusions that are appropriately drawn based on the data presented.

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available (please refer to the Data Availability Statement at the start of the manuscript PDF file)?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception. The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #3: No

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS Global Public Health does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #3: The authors have remarkably improved the quality of their work. I have no further comments.

Congratulations.

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

Do you want your identity to be public for this peer review? If you choose “no”, your identity will remain anonymous but your review may still be made public.

For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #3: Yes: Dr Sahabi Kabir Sulaiman

**********

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Data. Study dataset.

    This dataset comprises anonymized records of participants involved in the study in the format of Excel spreadsheet. It includes information on demographics, COVID-19 vaccination status, knowledge, attitudes, and perceptions related to COVID-19, as well as barriers and facilitators to COVID-19 vaccination. The dataset encompasses data on HIV and HIV and COVID dual stigma among participants.

    (XLSX)

    pgph.0003069.s001.xlsx (50.5KB, xlsx)
    Attachment

    Submitted filename: Response to Reviewers.docx

    pgph.0003069.s002.docx (24.3KB, docx)

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLOS Global Public Health are provided here courtesy of PLOS

    RESOURCES